This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APTX Aptinyx (APTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aptinyx Stock (NASDAQ:APTX) 30 days 90 days 365 days Advanced Chart Get Aptinyx alerts:Sign Up Key Stats Today's Range$0.09▼$0.1050-Day Range$0.06▼$0.1052-Week Range$0.01▼$0.72Volume231,126 shsAverage Volume1.32 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois. Read More Receive APTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter. Email Address APTX Stock News HeadlinesAptinyx Inc Com (OTC:APTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comApple Watch X: All the Rumors So FarAugust 25, 2024 | macrumors.comMHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market.August 8 at 2:00 AM | Weiss Ratings (Ad)Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOApril 23, 2024 | businesswire.comNew Leaf Venture Management III, L.L.C.'s Net WorthMarch 12, 2024 | benzinga.comPatrick J Heron's Net WorthFebruary 9, 2024 | benzinga.comBest Noise-Canceling Headphones for 2024January 13, 2024 | cnet.comAptinyx Inc APTXDecember 17, 2023 | morningstar.comMSee More Headlines APTX Stock Analysis - Frequently Asked Questions How were Aptinyx's earnings last quarter? Aptinyx Inc. (NASDAQ:APTX) released its earnings results on Tuesday, November, 9th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). When did Aptinyx IPO? Aptinyx (APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptinyx investors own include Plug Power (PLUG), Tesla (TSLA), Evofem Biosciences (EVFM), VBI Vaccines (VBIV), SCYNEXIS (SCYX), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). Company Calendar Last Earnings11/09/2021Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APTX CIK1674365 Webwww.aptinyx.com Phone(847) 871-0377FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book0.17Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:APTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptinyx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptinyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.